GPR151 and obesity due to melanocortin 4 receptor deficiency: Additionally, Gurtan et al. foundthatpLOF variants−,  in human populations were unstable in vitro and showed no significant BMI reduction in heterozygous or homozygouscarriers. Given these findings, GPR151antagonism is unlikely to be a viable treatment for obesity or diabetes.GPR151 may still play a role in metabolism, but more research is neededto detail the extent.